Press Release | May 19, 2026
Dragonfly Therapeutics Announces Encouraging Early Results from the Phase 1 for DF5112, its CCR6-Targeting Molecule
Read More
Press Release | May 12, 2026
Boehringer Ingelheim licenses preclinical antibody program from Immunitas Therapeutics to advance treatments for chronic inflammatory diseases
Read More
Press Release | March 2, 2026
Skyhawk Announces Australia’s Therapeutic Goods Administration Has Determined SKY-0515 for Huntington’s Disease Meets Eligibility Criteria for Registration via the Provisional Approval Pathway
Read More
Press Release | February 24, 2026
Nu-Tek BioSciences to Highlight Animal-Origin-Free Peptones, Supply Chain Strength at DCAT Week 2026
Read More
